Endocrinology · Dopamine Agonist
The FDA's acceptance of the supplemental application for PARLODEL is a significant regulatory milestone for Esjay Pharma, potentially strengthening its market position. This development warrants close monitoring as it may influence competitive dynamics in the endocrinology space.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 7/9/2026, 12:31:20 AM
Assessment confidence: 55% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.
The FDA's acceptance of the supplemental application for PARLODEL is a significant regulatory milestone for Esjay Pharma, potentially strengthening its market position. This development warrants close monitoring as it may influence competitive dynamics in the endocrinology space. Regulatory context from FDA (FDA AP — PARLODEL (SUPPL)) supports the near-term read. Assessment grounded in 17 ranked evidence items (3 high-relevance).
Portfolio teams should assess the potential market impact of this supplement and consider strategic positioning against competitors. The strongest clinical anchor is Pharmacokinetics of VC005 Tablets in Subjects With Renal Impairment and Normal Renal Function (ClinicalTrials.gov), moderate corpus alignment. In Endocrinology · Dopamine Agonist, 5 regulatory and 2 competitive items passed relevance filtering for Esjay Pharma.
The most relevant competitive pressure comes from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from FDA Accepts Supplemental NDA for NUPLAZID by ACADIA PHARMS. This acceptance may enhance Esjay Pharma's position in the market for dopamine agonists, potentially impacting competitors in the endocrinology space.
Regulatory risk is concentrated around FDA AP — PARLODEL (SUPPL) (FDA). Entity match (esjay pharma). Relevant agencies in corpus: FDA, MHRA.
Class 4 Medicines Defect Notification: Brancaster Pharma Limited, Benzylpenicillin benzathine 1.2 Million I.U. and 2.4 Million I.U. powder for suspension for injection, EL(26)A/30
MHRAmedium relevance
Moderate corpus alignment
FDA document
View sourceJuly 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee - 07/23/2026
FDAmedium relevance
Moderate corpus alignment
FDA document
View sourcePharmacy Compounding Advisory Committee Roster
FDAmedium relevance
Moderate corpus alignment
FDA document
View sourceReport on the State of Pharmaceutical Quality
FDAmedium relevance
Moderate corpus alignment
FDA document
View sourcePharmacokinetics of VC005 Tablets in Subjects With Renal Impairment and Normal Renal Function
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceEffects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Masked Controlled Clinical Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceStudy of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourcePomegranate Dietary Supplements in AUD and ALD
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceTo Assess Dose Proportionality and Pharmacokinetic Linearity of Saninova Tablets in Healthy Participants Under Fasting Conditions
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceFDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Accepts Supplemental NDA for NUPLAZID by ACADIA PHARMS
Humanexa Signalsmedium relevance
Moderate corpus alignment
A 3.6:1 myo-inositol to D-chiro-inositol ratio and antioxidant-based food supplement before IVF improves fertility in women with PCOS: a pilot observational retrospective cohort study.
PubMedhigh relevance
Mechanism alignment (IO )
FDA document
View sourceRarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceInsect-based models in pharmaceutical ecotoxicology: a bibliometric and narrative review.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceEffects of carnosine supplementation on physical endurance: a placebo-controlled randomized clinical trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceLavandula angustifolia as a dual pharmacological system: from essential oil to polyphenol-rich biomass.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe FDA's acceptance of the supplemental application for PARLODEL is a significant regulatory milestone for Esjay Pharma, potentially strengthening its market position. This development warrants close monitoring as it may influence competitive dynamics in the endocrinology space.
If approved, this supplement could enhance Esjay Pharma's market share in the dopamine agonist category, impacting revenue streams and competitive positioning against other players.
The acceptance of the supplemental application indicates a pathway towards potential approval, but the timeline and any additional data requirements will be critical for compliance and market readiness.
Monitor the timeline for the FDA's review and any subsequent announcements regarding approval or additional data requirements.
Track for follow-up milestones; no immediate action required.